Breaking News on Contract Research, Manufacturing & Clinical Trials

Phase I-II

Products

Download now!Data sheet

Orthotopic Brain Tumor Models Improved with Imaging - Molecular Imaging Inc.

14-Apr-2014 - Know more: enhance in vivo pharmacology with imaging. Recent tumor model development and informative imaging technologies have enabled the efficient and robust use of orthotopic models. These models have proven to be the most clinically relevant and predictive cancer models....
Download now!Technical / white paper

Forecasting strategies to optimize clinical trials - Almac Group

03-Mar-2014 - In a market that is constantly evolving, where rising complexities and costs associated with product development and clinical trial conduct present new clinical supply chain challenges, conventional forecasting methods may not provide an adequate solution.  Add to this the increasing...
Download now!Technical / white paper

Applying a Health- and Science- based Risk Assessment for Multi-Product Biologics manufacturing - Fujifilm

18-Nov-2013 - Over the last 10-15 years, it has become common practice to manufacture biologics intended for clinical trials (Investigational Medicinal Products, or IMPs) in multi-purpose facilities.This flexibility has been a key enabler in ensuring a flow of novel products, frequently targeting...
Download now!Case study

Controlled Release and Bioavailability Enhancement -

28-Oct-2013 - Metrics provides product development that leverages proprietary pharmaceutical technologies in the areas of: •    Customized Controlled Release Drug Delivery •    Bioavailability Enhancement •    Taste Masking (liquid and solid presentations)When applied appropriately, these technologies can deliver therapeutic and convenience benefits to...
Download now!Data sheet

505(b)(2): 10 Years and Running with 300+ Approvals - Camargo

21-Oct-2013 - In 2003, the FDA unleashed the 505(b)(2) pathway. With a record 47 approvals in 2012, the pathway is helping product developers secure up to 7 years of market exclusivity.Visit us at AAPS booth 4304 and read our white paper to learn more.
Watch now!On-Demand Supplier Webinar

New Guidelines for Stabilization of Proteins by Freeze Drying: Formulation and Process Heresy - Baxter

17-Oct-2013 - Over the years a number of informal guidelines or “rules” for the formulation and processing of proteins for freeze-drying have been developed. However, in recent years it has become obvious that some of these rules need modification. In this presentation,...
Download now!Technical / white paper

HEPATITS C VIRUS – RACE FOR TREATMENT - SGS

23-Sep-2013 - To understand why there is so much buzz in the pharmaceutical world for a better HCV treat­ment, as with most things, you have to start with history. This article will highlight the history, why there is a growing need for...
Download now!Technical / white paper

Patient Reminders: Improve Retention & Compliance - Cenduit

02-Sep-2013 - The average cost of a patient lost to follow-up is $5,000.  Read on to learn how to incorporate patient reminders into your protocol to reduce cost and resource wastage associated with patient noncompliance and early withdrawal. 
Download now!Technical / white paper

(b)(2) or not (b)(2)? That is the question. - Camargo

19-Aug-2013 - 505(b)(2) is more than a regulatory pathway - for many, it’s a unique strategy that can often result in product approval with lower risk, reduced development cost and faster speed to market. So, is (b)(2) for you? To find out...
Download now!Case study

Accelerating Lipid Drug Formulation with the Premier Expert System - Capsugel

11-Jul-2013 - Formulation scientists are increasingly pivotal to pharmaceutical product development. They are often faced with the daunting challenge of identifying the most suitable drug delivery platform among a myriad of options and developing and validating robust systems that address the challenges...
Download now!Technical / white paper

Understanding the 505(b)(2) Approval Pathway - Camargo

11-Jun-2013 - When it comes to developing a compound, the 505(b)(2) drug development pathway is not just a regulatory platform — it’s a different animal. This pathway offers a holistic approach for developing products that offer differentiated benefits with Lower Risk, Reduced...
Download now!Data sheet

505(b)(2): It’s A Different Animal - Camargo

13-May-2013 - 505(b)(2) is more than a regulatory pathway — for many, it’s a unique strategy that can often result in product approval with lower risk, reduced development cost and faster speed to market. So, is (b)(2) for you?
Watch now!On-Demand Supplier Webinar

Antibody Drug Conjugate Development and Manufacture - Piramal

03-May-2013 - With the recent approvals of brentuximab vedotin (Adcetris) and ado-trastuzumab emtansine (Kadcyla,T-DM1), antibody–drug conjugates (ADCs)are a rapidly growing area in oncology with great potential. Development and manufacture of ADCs can be a challenge with the requirement to handle both biologics...
Download now!Case study

Joint Risk Assessment During Technical Transfer – A Framework for Donor and Recipient Companies - Alkermes

22-Apr-2013 - Every technical (tech) transfer is different, with companies taking different paths toward reaching their goal. Each one presents a unique set of challenges. These challenges are most often technical, but at times they may also be business related. However all...
Download now!Technical / white paper

ePathology Improves Data Accuracy & Study Productivity! – Amicus Study Confirms - Aperio

20-Mar-2013 - With current glass slide methods, sharing and scoring slides within a study from one pathologist to another at a different organization or site, meant that slides had to be packed, shipped and tracked. Often the reading pathologist was required to...
Download now!Technical / white paper

What Makes 505(b)(2) Different? - Camargo

19-Mar-2013 - When it comes to developing a compound, the 505(b)(2) drug development pathway is not just a regulatory platform — it’s a different animal. This pathway offers a holistic approach for developing products that offer differentiated benefits with Lower Risk, Reduced...
Download now!Technical / white paper

Identifying the Product - Camargo

06-Feb-2013 - When it comes to developing a compound, the 505(b)(2) pathway can make changes to reference products for greater profit potential and lower risk. Camargo Pharmaceutical Services offers a clear process from concept through commercialization to identify products with documented market differentiation: Selection...
Watch now!Video

The Best of Both Worlds: Swiss Quality, Made in China -

05-Feb-2013 - Lonza brings you the best of both worlds with Swiss quality manufacturing of APIs available at our FDA approved facility in Nansha, China.  From backward integration to tailored production concepts for efficient manufacturing, Lonza offers sustainable solutions for regionally important...
Download now!Case study

Blinding Techniques for Inhaler Devices - Development of a Novel Blinding Methodology for a Market Leading DPI - Almac Group

21-Jan-2013 - Blinding inhalers for use in clinical studies is a challenging and specialised area of clinical trial supplies. In this case study, Almac provide a real life overview of their unique inhaler blinding services which have been successfully developed and validated,...
Download now!Case study

Alkermes successful approach to commercial-scale, final dosage manufacture of drug product containing highly potent API for a global pharmaceutical company. - Alkermes

18-Dec-2012 - As part of Alkermes plc, Alkermes Contract Pharma Services, provides solid oral dosage product development, scale–up and manufacturing services as well as sterile fill finish capabilities to the global pharmaceutical market. This case study demonstrates how a commercial manufacturing partnership...

Key Industry Events

 

Access all events listing

Our events, Events from partners...

Product Innovation